Concepedia

How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009–2014

Ilaria Marcianò, Ylenia Ingrasciotta, Francesco Giorgianni, Jenny Bolcato, Alessandro Chinellato, Roberta Pirolo, Annalisa Di Giorgio, Sonia Manna, Valentina Ientile, Rosa Gini,

BioDrugs · 2016 · 35 citations · 6 references

DOI

Concepts

References

6

The economics of biosimilars.

Erwin A. Blackstone, P Fuhr Joseph · PubMed · 2013 · 177 citations

, , +17

Saving money in the European healthcare systems with biosimilars

Robert Haustein · Generics and Biosimilars Initiative Journal · 2012 · 109 citations

, , +16

Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia

Matti Aapro, Paul Cornes, Ivo Abraham · Journal of Oncology Pharmacy Practice · 2011 · 105 citations

, , +17

Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)

Pere Gascón, Matti Aapro, Heinz Ludwig et al. · Supportive Care in Cancer · 2015 · 66 citations · Full text

, , +15

How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009–2013

Ylenia Ingrasciotta, Francesco Giorgianni, Jenny Bolcato et al. · BioDrugs · 2015 · 53 citations · Full text

, , +17